Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Finished Dosage Form Business and Assets of Xellia Pharmaceuticals for approximately $190 million on June 17, 2024. A cash consideration of $135 million will be paid by Hikma Pharmaceuticals PLC and an additional contingent consideration of up to $50 million cash, subject to the achievement of certain regulatory and commercial milestones. As a part of transaction, US finished dosage form business and assets, including a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and an R&D center in Zagreb, Croatia will be acquired.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,891 GBX | +0.85% |
|
-4.06% | +5.70% |
06-24 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
06-20 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.70% | 5.26B | |
+56.40% | 819B | |
-6.46% | 351B | |
+18.30% | 329B | |
+9.52% | 298B | |
+16.57% | 242B | |
+2.04% | 225B | |
+13.31% | 217B | |
+8.40% | 168B | |
-3.13% | 158B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals PLC agreed to acquire Finished Dosage Form Business and Assets of Xellia Pharmaceuticals for approximately $190 million.